在T2DM中依赖葡萄糖的胰岛素型多 (GIP) 的治疗潜力:过去,现在和未来
Soumik Das1, Harini Ravi1, Achsha Babu1
1Department of Bio-Medical Sciences, School of Bio Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, India.
葡萄糖依赖型胰岛素型多 (GIP) 显示了对2型糖尿病 (T2DM) 的治疗潜力. 研究探讨GIP的研究.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 是由于胰岛素抵抗而造成的全球健康问题.
- 胰岛素激素,GLP-1和GIP,调节葡萄糖平衡.
- 与GLP-1R不同,GIP受体 (GIPR) 对T2DM的治疗潜力正在研究中.
研究的目的:
- 检查GIP作为T2DM治疗剂的作用.
- 将涉及GIP的过去,现在和未来治疗场景进行比较.
- 研究GIP对胰腺β细胞功能,脂肪组织和脂质代谢的影响.
主要方法:
- 对GIP和T2DM现有的临床研究进行审查.
- 分析GIP的机械功能和受体相互作用.
- 探索GIP在相关疾病 (心血管,NAFLD,神经退行性,脏) 中的作用.
主要成果:
- 有证据表明GIP参与T2DM病理生理学.
- GIP影响胰腺β细胞功能,脂肪组织吸收和脂质代谢.
- 目前正在开发GIPR激应剂用于T2DM治疗.
结论:
- GIP为T2DM提供了一个有前途的治疗途径.
- 需要进一步的研究,以充分阐明GIP的机制和临床应用.
- 基于GIP的药物开发和再利用方面的进展为T2DM管理提供了潜力.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
08:03Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Dipeptidyl Peptidase 4 Inhibitors
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
